FOTIVDA tivozanib

Drug Class

VEGFR tyrosine kinase inhibitor

Mechanism

Selectively inhibits VEGFR-1, -2, and -3 receptor tyrosine kinases, blocking tumor vascularization and cell growth.

Approved Indication

Relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies, per its FDA approval.

What This Means For Patients

FOTIVDA is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2021) — Sources

Pivotal Clinical Evidence

• TIVO-3 — Rini et al., Lancet Oncol 2020 (NCT02627963) — Sources

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tivozanib-relapsed-or-refractory-advanced-renal-cell-carcinoma
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212904s000lbl.pdf